Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
In the latest session, Guardant Health Inc (NASDAQ: GH) closed at $106.89 down -0.63% from its previous closing price of $107.57. In other words, the price has decreased by -$0.63 from its previous closing price. On the day, 1.48 million shares were traded. GH stock price reached its highest trading level at $108.3 during the session, while it also had its lowest trading level at $103.8064.
Ratios:
For a deeper understanding of Guardant Health Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.12 and its Current Ratio is at 3.50.
Wolfe Research Upgraded its Peer Perform to Outperform on September 25, 2025, while the target price for the stock was maintained at $75.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jan 07 ’26 when Monroe Terilyn J. sold 10,031 shares for $112.08 per share. The transaction valued at 1,124,279 led to the insider holds 20,990 shares of the business.
Monroe Terilyn J. bought 10,031 shares of GH for $1,124,200 on Jan 07 ’26. On Dec 17 ’25, another insider, Tariq Musa, who serves as the Director of the company, sold 116 shares for $101.46 each. As a result, the insider received 11,769 and left with 7,993 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GH now has a Market Capitalization of 13882276864 and an Enterprise Value of 14218895360. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.32. Its current Enterprise Value per Revenue stands at 15.754 whereas that against EBITDA is -35.353.
Stock Price History:
The Beta on a monthly basis for GH is 1.64, which has changed by 1.8685334 over the last 52 weeks, in comparison to a change of 0.1726681 over the same period for the S&P500. Over the past 52 weeks, GH has reached a high of $113.91, while it has fallen to a 52-week low of $34.88. The 50-Day Moving Average of the stock is 4.75%, while the 200-Day Moving Average is calculated to be 65.45%.
Shares Statistics:
For the past three months, GH has traded an average of 2.54M shares per day and 2059650 over the past ten days. A total of 125.01M shares are outstanding, with a floating share count of 124.45M. Insiders hold about 3.81% of the company’s shares, while institutions hold 96.51% stake in the company. Shares short for GH as of 1767139200 were 10369455 with a Short Ratio of 4.08, compared to 1764288000 on 9245963. Therefore, it implies a Short% of Shares Outstanding of 10369455 and a Short% of Float of 8.36.
Earnings Estimates
. The current assessment of Guardant Health Inc (GH) involves the perspectives of 14.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.26 and low estimates of -$0.6.
Analysts are recommending an EPS of between -$1.67 and -$2.2 for the fiscal current year, implying an average EPS of -$1.81. EPS for the following year is -$1.44, with 16.0 analysts recommending between -$0.91 and -$2.31.
Revenue Estimates
A total of 15 analysts believe the company’s revenue will be $268.24M this quarter.It ranges from a high estimate of $270M to a low estimate of $267M. As of. The current estimate, Guardant Health Inc’s year-ago sales were $201.81MFor the next quarter, 15 analysts are estimating revenue of $271.81M. There is a high estimate of $284.9M for the next quarter, whereas the lowest estimate is $255.92M.
A total of 18 analysts have provided revenue estimates for GH’s current fiscal year. The highest revenue estimate was $970.8M, while the lowest revenue estimate was $967.8M, resulting in an average revenue estimate of $969.08M. In the same quarter a year ago, actual revenue was $739.02MBased on 21 analysts’ estimates, the company’s revenue will be $1.23B in the next fiscal year. The high estimate is $1.32B and the low estimate is $1.16B.
